SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

TSLA is under significant downward pressure as investors rotate out of growth stocks amid geopolitical instability and skepticism regarding the execution of its latest AI and infrastructure initiatives. The community remains deeply divided, with some buyers viewing the current price action as a long-term accumulation opportunity, while others express frustration over the stock's recent technical breakdown and the company's dependency on speculative future projects.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and price appreciation following its recent NYSE listing, with investors actively debating whether the high premium over its reported net asset value is justified by its exclusive exposure to high-profile private AI companies like Anthropic and OpenAI. Community discussion is dominated by the impact of a mandatory six-month lockup period on the majority of shares, which has created a tight float and sparked intense speculation about potential for further momentum or a sharp correction.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility and downward pressure as investors weigh recent acquisition activity against broader macroeconomic headwinds, including geopolitical tensions and fluctuating construction market sentiment. Despite the bearish pressure, the community remains actively divided, with many long-term shareholders continuing to express confidence in CEO Brad Jacobs' consolidation strategy while others closely monitor for the next M&A catalyst or integration updates.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to intense community debate surrounding the administration's aggressive stance on Iran and controversial threats involving the use of federal agents at airports. Investors and social media participants are heavily polarized, with vocal discourse focused on the company's financial volatility, the geopolitical implications of the unfolding conflict, and the broader influence of figures like Elon Musk in the current administration's policy decisions.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently drawing significant community attention as investors debate the impact of new institutional partnerships, exchange-traded fund developments, and the potential for long-term tokenization utility. While many in the community express deep frustration over recent price volatility, others are actively using the current market climate to accumulate positions, citing the project's role in institutional blockchain infrastructure as a primary driver for a future rebound.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

Crane Harbor Acquisition Corp. is trending as shareholders recently approved its merger with Xanadu Quantum Technologies, a milestone expected to establish the first publicly traded photonic quantum computing company under the ticker XNDU. Community discussion is heavily focused on the deal's potential for a low-float short-term squeeze, strategic partnerships with major tech industry leaders, and potential government funding support.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as market sentiment surges following high-profile industry discussions regarding the platform's role in the decentralized AI revolution. Investors are closely monitoring the upcoming supply halving and the rapid expansion of network subnets, which many in the community view as foundational infrastructure for the long-term AI-crypto convergence.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a massive Q4 booking report that significantly exceeded expectations, signaling robust long-term demand for AI-driven lithography equipment. Community discussion remains heavily focused on the company's unassailable moat as a 'foundational' AI player, with many traders debating the sustainability of current valuation highs despite strong buyback announcements and increased backlog visibility.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell is gaining traction as investors weigh geopolitical risks in the Middle East against the company's robust capital return program, including consistent multi-billion dollar share buybacks. The community is actively debating the stock's role as a hedge against energy supply volatility, while also tracking its strategic expansion in the LNG market and ongoing efforts to divest non-core chemical assets.

United States Commodity Funds LLC - United States Brent Crude Oil Fund

The BNO ticker is trending as market participants debate the intensity of Middle Eastern geopolitical tensions, with discussions centered on supply risks, production shutdowns, and the potential for severe market impacts if key shipping routes remain contested. Community members are actively analyzing the divergence between physical and paper oil prices while debating whether escalating conflict or recessionary pressures will dictate the future trajectory of crude prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been...

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Womens Cancers

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term...

Foresite Capital Management VI LLC Has $23.09 Million Holdings in Verastem, Inc. $VSTM

Foresite Capital Management VI LLC increased its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 104.9% during the third quarter, according to its most recent Form 13F filing with...

Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research

BTIG Research reissued a "buy" rating and set a $19.00 target price on shares of Verastem in a research note on Thursday...

Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?

The mean of analysts' price targets for Verastem (VSTM) points to a 159.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Jefferies Financial Group Inc. Increases Stake in Verastem, Inc. $VSTM

Jefferies Financial Group Inc. increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 48.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange...

Verastem (NASDAQ:VSTM) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded Verastem from a "sell" rating to a "hold" rating in a report on Saturday...

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Brokerages

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has...

<ul class="summary-bullets"><li>The company's Q4 adjusted loss was $0.48 per share, while revenue of $17.5 million beat expectations of $16.84 million.</li><li>Avmapki Fakzynja co-pack generated $17.5 million in Q4 revenue and $30.9 million in 2025 following FDA approval in May.</li><li>The KRAS cancer drug VS-7375 cleared multiple dose levels with no safety issues.</li></ul>Shares of Verastem, Inc. (VSTM) rose nearly 3% in after-hours trading on Wednesday, even after the cancer drug developer reported a quarterly earnings miss, as investors focused on early traction from its newly approved ovarian cancer therapy and a string of upcoming clinical milestones.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> jumped over 2% in Wednesday’s regular session.<h2 class="st-heading-2">VSTM Q4 Review</h2>The company reported an adjusted loss of $0.48 per share for the fourth quarter (Q4), slightly wider than analysts’ $0.50-per-share loss estimate, while revenue came in at $17.5 million, topping the $16.84 million consensus estimate.Revenue in the quarter was driven by sales of Avmapki Fakzynja co-pack, a combination therapy approved by the U.S. Food and Drug Administration (FDA) in May 2025 for patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).The therapy generated $17.5 million in net product revenue in Q4 and $30.9 million for the full year, marking the company’s first full year of commercial revenue from the drug following its accelerated approval.“2025 was a transformative year for us, highlighted by the landmark FDA approval of Avmapki Fakzynja co-pack,” CEO Dan Paterson said, adding that the treatment is seeing “positive response across the LGSOC community with gynecologic and medical oncologists.”Verastem ended 2025 with $205 million in cash, cash equivalents, and investments. The company said funds will support operations into the first half of 2027.<h2 class="st-heading-2">VS-7375 Cancer Drug Advances In Early Trials</h2>Investors also focused on updates related to VS-7375, Verastem’s oral KRAS G12D inhibitor being developed for solid tumors.The company said the therapy has cleared multiple dose levels in early studies with no dose-limiting toxicities, allowing dose escalation to continue to 1,200 mg once daily. A 600 mg daily dose in combination with Cetuximab, a form of cancer therapy, has also been cleared without safety concerns, with higher dose levels now being evaluated.Following feedback from the FDA, Verastem said it plans to pursue Phase 2 registration-directed studies for VS-7375 in several cancer indications, including second-line pancreatic ductal adenocarcinoma, second or third-line non-small cell lung cancer, and later-line colorectal cancer in combination with Cetuximab.<h2 class="st-heading-2">Verastem Flags Multiple Pipeline Catalysts</h2>Verastem outlined several upcoming milestones that could drive investor interest in the months ahead. The company expects to report early clinical data from the VS-7375-101 study in the first half of 2026 and select the recommended Phase 2 dose with Cetuximab, allowing it to begin a colorectal cancer combination expansion cohort later in the first half of 2026.Enrollment in combination dose-escalation cohorts is expected to be completed by mid-2026, while monotherapy expansion cohorts are projected to finish enrollment in the second half of 2026. The company also plans to select the recommended Phase 2 dose and begin pancreatic and lung cancer combination expansion cohorts in the second half of the year.Separately, Verastem said it plans to present updated data from the Ramp 201 trial of Avmapki Fakzynja at the Society of Gynecologic Oncology annual meeting in April, while longer-term development continues through the Ramp 301 Phase 3 trial, which is expected to report a topline primary endpoint readout in mid-2027.The company is also preparing an update on the Ramp 205 study, which evaluates the therapy in combination with chemotherapy for first-line metastatic pancreatic cancer, with results expected in the second quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for VSTM was ‘extremely bullish’ amid a 450% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vstm_ss_png_aa5fb80917.webp" alt="vstm ss.png" width="962" height="136"><figcaption>VSTM sentiment and message volume as of March 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/CrozrX/message/646623324">said</a>, “Phenomenal safety with VS-7375 and as a bonus, all resolved quickly!!”<stembedurl>https://stocktwits.com/CrozrX/message/646623324</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Universaal/message/646621923">said</a> they “like what I heard this is going $7 plus tomorrow”<stembedurl>https://stocktwits.com/Universaal/message/646621923</stembedurl>VSTM stock has declined 25% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss?

The company flagged several catalysts ahead, including early VS-7375 data in the first half of the year, and Ramp 205 pancreatic cancer study results in Q2.

Equity

Verastem Q4 Earnings Call Highlights

Verastem (NASDAQ:VSTM) executives said the company's transition to a commercial-stage business accelerated in 2025 following FDA approval of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTMVerastem Inc